ABS launches safer, more efficient struvite removal solution

Advanced Bacterial Sciences (ABS) announces the launch of its ground-breaking new product, Struvite Remover, revolutionising the Anaerobic Digestion (AD) industry by providing a more efficient, secure, and cost-effective solution to the ongoing challenge of struvite build-up.

Struvite is a crystalline mineral compound primarily composed of magnesium, ammonium and phosphate which solidifies in pipework where there is an excess of these elements. In AD plants, this build-up can reduce throughflow of feed, reducing biogas production and have a detrimental effect on the plant’s operations.

Current methods of struvite removal, often involve using hazardous chemicals like hydrochloric acid and formic acid, or physical methods, which not only pose safety risks for workers but also result in significant plant downtime, leading to production losses and increased maintenance costs. Moreover, these methods can corrode vital infrastructure, adding to the overall operational burden.

ABS’ Struvite Remover dissolves struvite build-up in less than four hours, offering multiple advantages over current methods, making it safer, more economical, and environmentally friendly. What sets ABS' Struvite Remover apart is its ability to convert the waste generated during the struvite treatment process into a resource that can be fed back into the AD plant, eliminating the need for costly waste disposal.

In a recent on-site trial conducted by ABS, the Struvite Remover achieved an outstanding 100% struvite removal rate in under two hours. This reduced the client's downtime by a staggering three hours, outperforming their existing methods and delivering tangible benefits from day one.

"Our Struvite Remover represents a significant leap forward for the AD industry, exceeding expectations with unparalleled efficiency. With our solution, we aim to minimise the need for manual intervention during operation, thus reducing the risk of accidents and injuries associated with traditional struvite removal methods." Says Oliver Tett, Business Development Director, ABS.

Administered by the ABS team, the Struvite Remover works over a period of two to four hours, depending on the size of the pipe. A high-powered pump is connected to the AD site's existing pipework, creating a closed loop, and the solution is pumped through the circuit, effectively removing struvite build-up.

The waste generated during the process can be safely reintroduced into the digestors following dilution to prevent harming the digestors' microbiology, making waste disposal cost-free and environmentally responsible. Using ABS’ Struvite Remover, AD plants can significantly cut operational costs and extend the lifespan of their equipment, leading to potential higher revenue generation.

Struvite Remover marks ABS' entry into the AD and Agricultural sector, signalling their commitment to pioneering science-driven solutions for advancing, enhancing, and streamlining waste management challenges in this domain. As they continue to break new ground with this innovative product, ABS is actively exploring additional avenues to leverage their expertise and further revolutionise waste management practices within this sector.

 

More news and updates 

DLRC achieves King’s Award for Enterprise in International Trade

DLRC Ltd has been honoured with the King’s Award for Enterprise, recognising its outstanding performance in international trade. This places DLRC among a select group of only 252 organisations in the UK to receive this prestigious award.

Optibrium partners with FMC Corporation to transform agrochemical discovery

Optibrium’s AI-powered discovery platform Cerella™ chosen by FMC to accelerate its agrochemical discovery pipeline.

Touchlight Genetics and NPL awarded grant to develop novel gene-length single-stranded genome editing template

Touchlight Genetics, in partnership with the National Physical Laboratory (NPL) have secured funding from Innovate UK under their Innovative Technologies: Nucleic Acid Medicines Manufacture, Round 2 call. 

PrecisionLife and Metrodora Institute launch clinical trials to accelerate treatment of ME/CFS and long Covid patients

Up to 1,000 patients being recruited into targeted precision medicine clinical trials expected to readout results as early as this year; trials are designed to provide validation of safety and effectiveness for novel diagnostics and innovative clinical care pathways in ME/CFS and Long Covid.

European Life Sciences sector primed for growth in 2024 driving real estate demand and investment opportunities

The European Life Science sector has been marked by strong growth and resilience in recent years and is set for significant expansion in 2024, driven by new medical treatments and both private and public funding according to JLL’s Life Sciences Industry & Real Estate Perspective report.

Ingenza expanding codABLE® gene design algorithm to aid recombinant protein production in yeast

Scottish CRDMO Ingenza has secured innovation funding to adapt its codABLE® machine learning platform to precisely control recombinant protein expression in the industrial yeast Pichia pastoris. This game-changing project will accelerate the development of therapeutics, enzymes and other proteins by harnessing machine learning to fine-tune codon usage, ensuring seamless compatibility with the production host and maximising production yields.

Arecor and Medtronic Diabetes establish collaboration to develop novel thermostable insulin for implantable pump delivery

Medtronic to fund Arecor’s development of Arestat™ enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination with a next-generation implantable pump

Infinitopes secures £12.8 million seed financing to enhance its Precision ImmunomicsTM antigen discovery technologies

Infinitopes Precision Immunomics, an integrated cancer biotech combining world-leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the completion of a £12.8 million seed funding round led by Octopus Ventures.

Business Opportunity: Advance your workforce with a Bioscience Degree Apprenticeship

Manchester Metropolitan University have opened applications for the Laboratory Science Degree Apprenticeships in Bioscience. New cohorts are set to begin in September.

Poolbeg Pharma plc announces exclusive option agreement to acquire Orphan Drug Candidate for Behçet's Disease

Poolbeg Pharma plc announces that it has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX) for the treatment of oral ulcers in patient's suffering from Behçet's Disease.

 

More within